Clinical Trials

315 enrolled 11 charts

Breast Neoplasms

NCT03554044 2025-05-21

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

20 enrolled

Breast Neoplasms

NCT06965361 2025-05-16

TIL; PD1; PDL1

Completed

54 enrolled

Triple Negative Breast Neoplasms

NCT01818063 2025-04-30

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

9 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

189 enrolled

BreastGynecologic

Triple Negative Metastatic Breast Cancer

NCT01815242 2025-02-27

ADAPT

336 enrolled

Breast Neoplasms

NCT02163694 2025-02-19

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

513 enrolled 16 charts

Breast Neoplasms

NCT02531932 2025-02-19

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

64 enrolled

Breast Neoplasms

NCT06618014 2025-01-16

NeoTOP

51 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03206203 2024-12-12

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

106 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02819518 2024-11-27

KEYNOTE-355

882 enrolled 41 charts 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02009449 2024-11-15

IVY

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

353 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02339532 2024-11-08

NeoTOP

86 enrolled

Breast Neoplasms

NCT03267316 2024-08-22

CANFOUR

BreastGastrointestinalThoracic

167 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04799249 2024-08-01

PRESERVE 2

194 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

54 enrolled

Triple Negative Breast Neoplasms

NCT04957212 2024-07-26

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

214 enrolled 16 charts

HER2-positive Breast Cancer

NCT05112536 2024-03-12

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

24 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02620280 2024-03-06

NeoTRIPaPDL1

278 enrolled

Carcinoma, Ductal, Breast, Triple Negative Breast Neoplasms

NCT00618657 2024-02-28

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

127 enrolled 12 charts

Breast Neoplasms

NCT03853707 2024-02-20

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

28 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT03989037 2023-12-27

A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

580 enrolled

HER2-positive Early Breast Cancer

NCT02897375 2023-10-10

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

71 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT03121352 2023-10-06

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

30 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT01618136 2023-06-18

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

BreastGynecologicLymphoidOther hematologic neoplasm

41 enrolled

Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Triple Negative Breast Neoplasms

NCT00432172 2023-04-03

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

189 enrolled 17 charts

Breast Neoplasms

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

47 enrolled 13 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

83 enrolled

Triple Negative Breast Neoplasms

NCT02983045 2023-03-13

PIVOT-02

BreastDermatologicGastrointestinalGenitourinaryThoracic

557 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT00608972 2023-02-08

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

31 enrolled 11 charts

Breast Neoplasms

NCT03732391 2023-01-31

Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)

22 enrolled

Breast Neoplasms

NCT03499899 2023-01-30

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

88 enrolled 35 charts

Triple Negative Breast Neoplasms

NCT02978495 2022-12-28

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

154 enrolled

BreastGynecologic

BRCA1 Hereditary Breast and Ovarian Cancer Syndrome

NCT03735966 2022-12-01

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

75 enrolled

HER2 Positive Breast Cancer

NCT01795586 2022-10-31

A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients

19 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02419742 2022-10-12

Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

Phase 4 Completed

110 enrolled 10 charts

Breast Neoplasms

NCT03154749 2022-09-01

DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

93 enrolled

Triple Negative Breast Neoplasms

NCT02789657 2022-05-19

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

32 enrolled 10 charts